Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2025-02-17 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
关于使用自有闲置资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It includes specifics about the amounts, types of financial products, expected yields, investment directions, and risk controls. The document is a formal disclosure about the company's capital management activities, specifically about entrusted financial management and investment of idle funds. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an annual or interim report, nor an earnings release. It is not a regulatory certification or a voting result announcement. The content fits best with a Capital/Financing Update as it relates to the company's financing activities and capital usage updates. The document length is sufficient and the content is substantive about financing activities, not just a brief notice or report publication announcement.
2025-02-17 Chinese
关于使用自有闲置资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It includes specifics about the amounts, types of financial products, expected yields, investment directions, and risk control measures. The document is not a financial report like an annual or interim report, nor is it a call transcript or management report. It is a disclosure about capital management activities, specifically the use of idle funds for entrusted financial management, which relates to financing or capital updates. The document is longer than 5,000 characters and contains substantive details about the financing activities, not just an announcement of a report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-02-09 Chinese
关于在研产品取得药品注册申请受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the acceptance of a drug registration application by the National Medical Products Administration. It details the receipt of a 'Notice of Acceptance' for a drug under development, including product specifications and regulatory approval status. The document is short (772 characters) and serves as a formal announcement of a regulatory milestone rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-02-05 Chinese
关于使用部分闲置募集资金委托理财进展的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It includes specifics about the authorized entrusted financial management, amounts, product types, expected yields, risk control measures, and a summary of both ongoing and matured entrusted financial products. The document is a disclosure about the company's use of idle raised funds for financial management purposes, which is a capital/financing update rather than a full financial report, earnings release, or regulatory filing. It does not contain comprehensive financial statements or management discussion but focuses on the company's capital usage and investment activities related to raised funds. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (5352 characters) and content support this classification with high confidence.
2025-01-22 Chinese
关于使用自有闲置资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It includes specifics about the amounts, types, expected yields, investment directions, and risk controls related to entrusted financial management products. The document is a regulatory disclosure about the company's financing activities, specifically the use of idle funds for investment in financial products, which is a capital/financing update. It is not a full financial report, audit, or earnings release, nor is it a meeting announcement or voting result. The document length is 5761 characters, which is sufficient for a detailed announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-01-22 Chinese
关于使用自有闲置资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It details the authorization, amounts, types of financial products purchased, risk control measures, and the status of these investments. The content focuses on updates about capital usage and investment activities rather than financial results, management changes, or regulatory certifications. There is no indication that this is a full financial report, earnings release, or management discussion. The document is a specific update on financing activities related to the company's capital management and investment of idle funds. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about financing activities, not just an announcement of a report or a certification, so it is not RPA or RNS.
2025-01-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.